Genmab A (GMAB) Cash from Financing Activities (2018 - 2026)
Genmab A (GMAB) reported Cash from Financing Activities of -$177.0 million for Q1 2026, down 1261.54% on a YoY basis from $15.2 million in Q1 2025, and down 742.86% quarter-over-quarter from -$21.0 million in Q3 2025.
Genmab A (GMAB) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Genmab A has reported Cash from Financing Activities for 7 years, with the latest figure at -$177.0 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 1261.54% year-over-year to -$177.0 million; the trailing twelve-month figure through Mar 2026 stood at -$630.0 million (up 44.98% YoY), and the FY2025 full-year result was $4.8 billion, up 946.11% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$177.0 million, down from -$21.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was -$13.0 million in Q1 2025, with the low at -$566.0 million in Q4 2024.
- Historically, Cash from Financing Activities has averaged -$215.1 million across 4 years, with a median of -$89.0 million in 2023.
- Annual changes were most pronounced in 2025 — Cash from Financing Activities jumped 84.71% — and 2026, when it slumped 1261.54%.
- Genmab A's Cash from Financing Activities stood at -$89.0 million in 2023, then tumbled by 535.96% to -$566.0 million in 2024, then surged by 96.29% to -$21.0 million in 2025, then slumped by 742.86% to -$177.0 million in 2026.
- The last three Cash from Financing Activities figures came in at -$177.0 million (Q1 2026), -$21.0 million (Q3 2025), and -$419.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 85,464.43 |
| 10 | Genmab A | 48.34 Bn | 46.82 Bn | 831.00 Mn | -177.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -177.00 Mn |
| Mar 31, 2026 | -177.00 Mn |
| Sep 30, 2025 | -21.00 Mn |
| Sep 30, 2025 | -21.00 Mn |
| Jun 30, 2025 | -419.00 Mn |
| Jun 30, 2025 | -419.00 Mn |
| Mar 31, 2025 | -13.00 Mn |
| Mar 31, 2025 | -13.00 Mn |
| Dec 31, 2024 | -566.00 Mn |
| Dec 31, 2024 | -566.00 Mn |
| Sep 30, 2024 | -41.00 Mn |
| Sep 30, 2024 | -41.00 Mn |
| Jun 30, 2024 | -525.00 Mn |
| Jun 30, 2024 | -525.00 Mn |
| Mar 31, 2024 | -85.00 Mn |
| Mar 31, 2024 | -85.00 Mn |
| Dec 31, 2023 | -89.00 Mn |
| Dec 31, 2023 | -89.00 Mn |
| Sep 30, 2020 | 19.00 |
| Sep 30, 2020 | 19.00 |